% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Heininger:282938,
author = {Heininger, Hannah and Feng, Xiao and Altunkaya, Alp and
Zheng, Fang and Stockinger, Florian and Wefers, Benedikt and
Müller, Stephan A and Giesbertz, Pieter and Tschirner,
Sarah and Shqau, Dorina and Adelsberger, Helmuth and
Ponomarenko, Alexey and Fenzl, Thomas and Alzheimer,
Christian and Lichtenthaler, Stefan F and Huth, Tobias},
title = {{BACE}1 regulates sleep–wake cycle through both enzymatic
and non–enzymatic actions},
journal = {EMBO reports},
volume = {Advance online publication},
issn = {1469-221X},
address = {[London]},
publisher = {Nature Publishing Group UK},
reportid = {DZNE-2025-01399},
pages = {-},
year = {2025},
abstract = {The β-secretase BACE1 has become a prime target in
Alzheimer’s disease (AD) therapy, because it drives the
production of pathogenic amyloid β peptides. However,
clinical trials with BACE1-targeting drugs were halted due
to adverse effects on cognitive performance. We propose here
that cognitive impairment by BACE1 inhibitors may be a
corollary of a higher function of BACE1 related to proper
sleep regulation. To address non-enzymatic effects of BACE1
on ion channels likely involved in the sleep-wake cycle, we
analyze sleep patterns in both BACE1-KO mice and a newly
generated transgenic line expressing a proteolysis-deficient
BACE1 variant (BACE1-KI). We find that BACE1-KI and BACE1-KO
mice display common and distinct sleep-wake disturbances.
Compared with their respective wild-type littermates, both
mutant lines sleep less during the light phase (when they
preferentially rest). Furthermore, transition rates between
wake and sleep states are altered, as are sleep spindles and
EEG power spectra mainly in the gamma range. Thus, a better
understanding of how BACE1 interferes with sleep-modulated
behaviors is needed if clinical trials with BACE1-targeted
inhibitors are to resume.},
cin = {AG Lichtenthaler / AG Wurst},
ddc = {570},
cid = {I:(DE-2719)1110006 / I:(DE-2719)1140001},
pnm = {352 - Disease Mechanisms (POF4-352)},
pid = {G:(DE-HGF)POF4-352},
typ = {PUB:(DE-HGF)16},
doi = {10.1038/s44319-025-00604-4},
url = {https://pub.dzne.de/record/282938},
}